217 related articles for article (PubMed ID: 11096437)
1. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases.
Alisky JM; Davidson BL
Hum Gene Ther; 2000 Nov; 11(17):2315-29. PubMed ID: 11096437
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis.
Wang LJ; Lu YY; Muramatsu S; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Matsushita T; Hanazono Y; Kume A; Nagatsu T; Ozawa K; Nakano I
J Neurosci; 2002 Aug; 22(16):6920-8. PubMed ID: 12177190
[TBL] [Abstract][Full Text] [Related]
3. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.
Kaspar BK; Lladó J; Sherkat N; Rothstein JD; Gage FH
Science; 2003 Aug; 301(5634):839-42. PubMed ID: 12907804
[TBL] [Abstract][Full Text] [Related]
4. Cellular and molecular approaches to motor neuron therapy in amyotrophic lateral sclerosis and spinal muscular atrophy.
O'Connor DM; Boulis NM
Neurosci Lett; 2012 Oct; 527(2):78-84. PubMed ID: 22579818
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease.
Tu PH; Gurney ME; Julien JP; Lee VM; Trojanowski JQ
Lab Invest; 1997 Apr; 76(4):441-56. PubMed ID: 9111507
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice.
Towne C; Setola V; Schneider BL; Aebischer P
Mol Ther; 2011 Feb; 19(2):274-83. PubMed ID: 21102563
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis.
Kostic V; Jackson-Lewis V; de Bilbao F; Dubois-Dauphin M; Przedborski S
Science; 1997 Jul; 277(5325):559-62. PubMed ID: 9228005
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 expression by retrograde transport of adenoviral vectors with Cre-loxP recombination system in motor neurons of mutant SOD1 transgenic mice.
Yamashita S; Mita S; Arima T; Maeda Y; Kimura E; Nishida Y; Murakami T; Okado H; Uchino M
Gene Ther; 2001 Jul; 8(13):977-86. PubMed ID: 11438832
[TBL] [Abstract][Full Text] [Related]
9. [Experimental approach to the gene therapy of motor neuron disease with the use of genes hypoxia-inducible factors].
Ismailov ShM; Barykova IuA; Shmarov MM; Tarantul VZ; Barskov IV; Kucherianu VG; Brylev LV; Logunov DIu; Tutykhina IL; Bocharov EV; Zakharova MN; Naroditskiĭ BS; Illarioshkin SN
Genetika; 2014 May; 50(5):591-601. PubMed ID: 25715475
[TBL] [Abstract][Full Text] [Related]
10. Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.
Towne C; Aebischer P
Methods Mol Biol; 2009; 555():87-108. PubMed ID: 19495690
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for amyotrophic lateral sclerosis.
Federici T; Boulis NM
Neurobiol Dis; 2012 Nov; 48(2):236-42. PubMed ID: 21889591
[TBL] [Abstract][Full Text] [Related]
12. [Restorative therapy in amyotrophic lateral sclerosis].
Aoki M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Nov; 32(5-6):287-92. PubMed ID: 23373317
[TBL] [Abstract][Full Text] [Related]
13. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.
Wang H; Yang B; Qiu L; Yang C; Kramer J; Su Q; Guo Y; Brown RH; Gao G; Xu Z
Hum Mol Genet; 2014 Feb; 23(3):668-81. PubMed ID: 24108104
[TBL] [Abstract][Full Text] [Related]
14. Gene-based treatment of motor neuron diseases.
Federici T; Boulis NM
Muscle Nerve; 2006 Mar; 33(3):302-23. PubMed ID: 16228969
[TBL] [Abstract][Full Text] [Related]
15. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease.
Lambrechts D; Carmeliet P
Biochim Biophys Acta; 2006; 1762(11-12):1109-21. PubMed ID: 16784838
[TBL] [Abstract][Full Text] [Related]
16. Cervical spinal cord delivery of a rabies G protein pseudotyped lentiviral vector in the SOD-1 transgenic mouse. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004.
Tanase K; Teng Q; Krishnaney AA; Liu JK; Garrity-Moses ME; Boulis NM
J Neurosurg Spine; 2004 Jul; 1(1):128-36. PubMed ID: 15291033
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy for ALS: progress and prospects.
Azzouz M
Biochim Biophys Acta; 2006; 1762(11-12):1122-7. PubMed ID: 16806843
[TBL] [Abstract][Full Text] [Related]
18. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model.
Corti S; Locatelli F; Papadimitriou D; Del Bo R; Nizzardo M; Nardini M; Donadoni C; Salani S; Fortunato F; Strazzer S; Bresolin N; Comi GP
Brain; 2007 May; 130(Pt 5):1289-305. PubMed ID: 17439986
[TBL] [Abstract][Full Text] [Related]
19. Intracerebroventricular Delivery in Mice for Motor Neuron Diseases.
Nizzardo M; Rizzuti M
Methods Mol Biol; 2017; 1565():229-239. PubMed ID: 28364247
[TBL] [Abstract][Full Text] [Related]
20. Amyotrophic lateral sclerosis and Alzheimer disease. Lessons from model systems.
Price DL; Wong PC; Borchelt DR; Pardo CA; Thinakaran G; Doan AP; Lee MK; Martin LJ; Sisodia SS
Rev Neurol (Paris); 1997 Sep; 153(8-9):484-95. PubMed ID: 9683997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
